Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged \>=50 years~* Varicella history-positive or residence for \>30 years in a country with endemic VZV infection~Exclusion Criteria:~* Febrile illness~* History of hypersensitivity or anaphylactoid reaction to any of the vaccine components~* Prior herpes zoster episode clinically diagnosed or exposure to varicella or herpes zoster within the 4 weeks prior to vaccination~* Prior receipt of varicella or zoster vaccine~* Active untreated tuberculosis~* Thrombocytopenia, any other coagulation disorder contraindicating intramuscular injection~* Receipt of medication / vaccine that may interfere with study assessments~* Known or suspected immune dysfunction~* User of recreational / illicit drugs or subject with alcohol abuse or dependence within the last year~* Any condition that might interfere with the interpretation of the study,

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ZOSTAVAX intramuscular (IM) route (Type: EXPERIMENTAL): Single dose of 0.65 mL via IM injection
- ZOSTAVAX subcutaneous (SC) route (Type: ACTIVE_COMPARATOR): Single dose of 0.65 mL via SC injection

Based on this trial design, predict the completion outcome and termination type (if applicable).